Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Three federal agencies announced the creation of a new taskforce to provide timely recommendations to laboratories for rapid implementation of…
By Steve Selbst bio
The purpose of this article is to help you, as a provider, to focus on three key items to look for in payer contracts that will help you to get profitable contracts in place…
From - Diagnostic Testing & Emerging Technologies
The American Society of Clinical Oncology endorsed the American Pathologists' practice guidelines for human papillomavirus (HPV) testing in…
From - Diagnostic Testing & Emerging Technologies
A laboratory-initiated, online effort to reach cancer patients' relatives coupled with discounted genetic tests can increase rates of cascade testing, according to…
From - Diagnostic Testing & Emerging Technologies
Prenatal diagnostics have evolved from conventional cytogenetic analysis to increasingly chromosomal microarray analysis, within the last…
From - Diagnostic Testing & Emerging Technologies
Elevated donor-derived, cell-free DNA (ddcfDNA) in the 3 months post-lung transplant can identify clinically silent allograft injury and…